Domino effect: Ipsen follows Biovail in dumping Santhera's fipamezole
This article was originally published in Scrip
Ipsen has returned the rights to Santhera Pharmaceuticals' Phase II investigational treatment for levodopa-induced dyskinesia in Parkinson's disease, forgoing the €13 million upfront payment it made when it signed the deal. But it was only a matter of time: just weeks after Ipsen acquired rights to fipamezole for territories outside the US and Japan back in September 2010, a significant factor in the strategic rationale for the deal evaporated with the discontinuation by Biovail of its own work on the product.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.